# Aligos Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aligos-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.aligos.com
- Total disclosed funding: $186M
- Latest round: Series B (Dec 23, 2019)
- Investors on record: 10

## About

Based in California, US, and founded in 2018, Aligos Therapeutics, Inc. develops targeted antiviral therapies for viral infections and liver diseases. The company was co-founded by Lawrence Blatt and Leonid Beigelman. In October 2020, the company went public in Nasdaq Global Market.

The company develops therapies for the treatment of chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), and other viral infections.

## Funding rounds

- Series B, Dec 23, 2019, $85M — Versant Ventures, Novo Holdings, Vivo Capital, Wellington Management, Roche Venture Fund, Cormorant Asset Management, Boxer Capital, Pivotal Life Sciences, Janus Henderson Investors, Logos Capital
- Series A, Jun 1, 2018, $101M — Versant Ventures, Novo Holdings, Vivo Capital, Roche Venture Fund

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Novo Holdings — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A, Series B
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A, Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series B
- Janus Henderson Investors — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B